Keytruda shows nearly 40% CR in high-risk non-muscle invasive bladder cancer unresponsive to standard of care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a phase II trial evaluating Keytruda (pembrolizumab) for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease (Cohort A).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login